Pfizer rejects Moderna claim it copied Covid vaccine, accuses rival of rewriting history

Pfizer rejects Moderna claim it copied Covid vaccine, accuses rival of rewriting history


Pfizer has rejected allegations made by rival Moderna that its Covid-19 vaccine is a copy, accusing the Boston biotech company of rewriting history to lay claim to technology developed by a field of scientists over many years.

Pfizer asked a federal court in Massachusetts on Monday to dismiss Moderna’s lawsuit seeking monetary damages for alleged patent violations related to the Boston company’s Covid vaccine. Pfizer asked the court to stop Moderna from suing it or its partners again over three alleged patent infringements.

Moderna, in a complaint filed in August, accused Pfizer of copying two key pieces of technology that make the messenger RNA Covid vaccines possible.

Moderna accused Pfizer of using the same modification to mRNA that keeps the molecule stable long enough to program human cells to produce the crucial spike protein that triggers an immune response against Covid.

Moderna also accused Pfizer of using the same full-length spike protein in its Covid shots. Moderna says it demonstrated a full spike produced an immune response in 2015 when it developed an mRNA vaccine against the Middle East Respiratory Syndrome. That vaccine never went to market.

“The Moderna inventions that Pfizer and BioNTech chose to copy were foundational for the success of their vaccine,” the company claimed.

Pfizer and its German partner BioNTech vigorously rejected those allegations, saying the technological building blocks for the vaccines were developed by a field of research scientists before the pandemic began. They accused Moderna of trying to “place itself in the spotlight alone.”

“Moderna is wrong, and its revisionist history is not based on fact. Pfizer and BioNTech did not copy Moderna’s technology,” Pfizer said in its response. “Rather, Pfizer and BioNTech independently developed their vaccine by utilizing innovation from their respective scientists and relying upon decades of research conducted by others before the pandemic began.”

Pfizer said the modification to mRNA was developed by research scientists at the University of Pennsylvania, one of whom is now an executive at BioNTech. It rejected Moderna’s claim to own the full-length spike protein technology. Pfizer said scientists have worried about coronaviruses since the 2003 SARS outbreak and by 2009 scientists understood the full-length spike induced a strong immune response.

Pfizer and Moderna have generated tens of billions of dollars in revenue from the Covid vaccines and generated windfall profits since the shots were first authorized in December 2020.

Moderna is asking the court to award it monetary damages since March 2022 including royalties and lost profits with interest. The company is also seeking enhanced damages up to three times the amount of compensatory damages found.



Source

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here
Health

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here

Wall Street is optimistic that Olema Pharmaceutical could be developing the next major breakthrough breast cancer treatment. Earlier this month, the company announced promising clinical data for its lead candidate palazestrant, an oral medication that is being evaluated in several trials for estrogen receptor-positive, or ER+, breast cancer. Shares of the clinical-stage biopharmaceutical company are up […]

Read More
This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’
Health

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’

It’s been a stellar few months for shares of San Francisco-based biotech company Rigel Pharmaceuticals, which has approved treatments for rheumatology and oncology — as well as potential new drugs in the pipeline. The stock has jumped about 50% in just the last three months, earning it a spot on CNBC’s list of top performing […]

Read More
We’re raising our Eli Lilly price target — what a difference a quarter makes
Health

We’re raising our Eli Lilly price target — what a difference a quarter makes

Eli Lilly shares jumped Thursday after the drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications. The company also raised its full-year sales outlook for the second time in a row, inspiring confidence in the trajectory of the franchise. Revenue in the three months ended Sept. 30 jumped 54% year […]

Read More